Inclusion Criteria:

- Patients must have recurrent or persistent epithelial ovarian, fallopian tube, or
primary peritoneal carcinoma; histologic documentation of the original primary tumor
is required via the pathology report

- Patients with the following histologic epithelial cell types are eligible: Serous
adenocarcinoma, endometrioid adenocarcinoma, mucinous adenocarcinoma,
undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma,
transitional cell carcinoma, malignant Brenner's Tumor, or adenocarcinoma not
otherwise specified (N.O.S.)

- All patients must have measurable disease as defined by RECIST 1.1; measureable
disease is defined as at least one lesion that can be accurately measured in at least
one dimension (longest dimension to be recorded); each lesion must be >= 10 mm when
measured by CT, MRI or caliper measurement by clinical exam; or >= 20 mm when
measured by chest x-ray; lymph nodes must be >= 15 mm in short axis when measured by
CT or MRI

- Patients must have at least one "target lesion" to be used to assess response on this
protocol as defined by RECIST 1.1; tumors within a previously irradiated field will
be designated as "non-target" lesions unless progression is documented or a biopsy is
obtained to confirm persistence at least 90 days following completion of radiation
therapy

- Patients must not be eligible for a higher priority GOG protocol, if one exists; in
general, this would refer to any active GOG Phase III or Rare Tumor protocol for the
same patient population

- Patients must have a GOG Performance Status of 0, 1, or 2

- Recovery from effects of recent surgery, radiotherapy, or chemotherapy

- Patients should be free of active infection requiring antibiotics (with the
exception of uncomplicated UTI)

- Any hormonal therapy directed at the malignant tumor must be discontinued at
least one week prior to registration; continuation of hormone replacement
therapy is permitted

- Any other prior therapy directed at the malignant tumor, including biological
and immunologic agents, must be discontinued at least three weeks prior to
registration

- Patients must have had one prior platinum-based chemotherapeutic regimen for
management of primary disease containing carboplatin, cisplatin, or another
organoplatinum compound; this initial treatment may have included non-cytotoxic
therapy, intraperitoneal therapy, high-dose therapy, consolidation, or extended
therapy administered after surgical or non-surgical assessment

- Patients must be considered platinum resistant or refractory according to the
following criteria:

- Patients must have had progression of disease on or within 6 months of their
last platinum dose

- Progression of disease is defined according to RECIST 1.1

- The development of CA125 elevation on or within 6 months of last platinum
treatment, in the absence of radiographic progression according to RECIST 1.1,
is not considered platinum resistance for the purposes of this study

- Patients who have NOT received prior therapy with taxane-based chemotherapy MUST
receive a second regimen that includes paclitaxel or docetaxel

- Patients must be considered paclitaxel-resistant, i.e., have had a treatment-free
interval following paclitaxel of less than six months, or have progressed during
paclitaxel-based therapy

- Patients must have NOT received any additional cytotoxic chemotherapy for management
of recurrent or persistent disease, including retreatment with initial chemotherapy
regimens except as noted above; (note: Optimal evaluation of the safety and efficacy
of new chemotherapy regimens is best performed in patients with minimal prior
therapy; non-investigational therapy, such as retreatment with platinum and/or
paclitaxel, is non-curative in the setting of recurrent disease, and can generally be
safely administered to patients following participation in a phase II trial)

- Patients are allowed to receive, but are not required to receive, one additional
non-cytotoxic regimen for management of recurrent or persistent disease according to
the following definition:

- Non-cytotoxic (biologic or cytostatic) agents include (but are not limited to)
monoclonal antibodies, cytokines, and small-molecule inhibitors of signal
transduction

- Absolute neutrophil count (ANC) greater than or equal to 1,500/mcl, equivalent to the
NCI Common Terminology Criteria (CTCAE v3.0) grade 1

- Platelets greater than or equal to 100,000/mcl

- Creatinine less than or equal to 1.5 x institutional upper limit normal (ULN), per
CTCAE v.3.0 grade 1

- Bilirubin less than or equal to 1.5 x ULN (CTCAE v.3.0 grade 1)

- SGOT (AST) less than or equal to 3 x ULN (per the CTCAE v.3.0 grade 1)

- Alkaline phosphatase less than or equal to 2.5 x ULN (CTCAE v.3.0 grade 1)

- Neuropathy (sensory and motor) less than or equal to the CTCAE v3.0 grade 1

- Patients must have signed an approved informed consent and authorization permitting
release of personal health information

- Patients must meet pre-entry requirements

- Patients of childbearing potential must have a negative serum pregnancy test prior to
the study entry and be practicing an effective form of contraception

Exclusion Criteria:

- Patients who have had prior therapy with Belinostat (PXD101) or other HDAC inhibitors

- Patients who have received radiation to more than 25% of marrow-bearing areas

- Patients with a history of other invasive malignancies, with the exception of
non-melanoma skin cancer, and other specific malignancies as noted below, are
excluded if there is any evidence of other malignancy being present within the last
five years; patients are also excluded if their previous cancer treatment
contraindicates this protocol therapy

- Patients who have received prior radiotherapy to any portion of the abdominal cavity
or pelvis OTHER THAN for the treatment of ovarian cancer are excluded; prior
radiation for localized cancer of the breast, head and neck, or skin is permitted,
provided that it was completed more than three years prior to registration, and the
patient remains free of recurrent or metastatic disease

- Patients who have received prior chemotherapy for any abdominal or pelvic tumor OTHER
THAN for the treatment of ovarian cancer are excluded; patients may have received
prior adjuvant chemotherapy for localized breast cancer, provided that it was
completed more than three years prior to registration, and that the patient remains
free of recurrent or metastatic disease

- Patients must not use concomitant medications on PXD infusion days that may cause
Torsade de Pointes; medications associated with this risk include:

- Amiodarone, Arsenic trioxide, Bepridil, Cisapride, Disopyramide, Dofetilide,
Droperidol, Erythromycin, Felbamate, Flecainide, Fluoxetine, Halofantrine,
Haloperidol, Ibutilide, Levofloxacin, Mesoridazine, Pentamidine, Procainamide,
Quinidine, Sotalol, Sparfloxacin, or Thioridazine

- Patients with significant cardiovascular disease defined as:

- Unstable angina pectoris, uncontrolled hypertension (blood pressure > 150/90
despite maximal medical therapy), congestive heart failure related to primary
cardiac disease, any condition requiring anti-arrhythmic therapy, ischemic or
severe valvular heart disease, or history of myocardial infarction within 6
months of trial entry

- Patients who are pregnant or nursing